12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD

October 31, 2013 updated by: Boehringer Ingelheim

A Randomized, Double-blind, Double-dummy, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Comparison of 12-week Treatment of Two Doses (5 Mcg and 10 Mcg) of Tiotropium Inhalation Solution Delivered by the Respimat Inhaler, Placebo and Ipratropium Bromide Inhalation Aerosol (MDI) i

The primary objective was to compare the bronchodilator efficacy of two doses (5 mcg and 10 mcg) of tiotropium inhalation solution delivered by the Respimat inhaler once daily to placebo and to ipratropium bromide MDI four times daily in patients with COPD. The secondary objective was to compare the safety of tiotropium inhalation solution delivered by the Respimat to placebo and ipratropium bromide MDI.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
491

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • British Columbia
      • Vancouver, British Columbia, Canada
        • Boehringer Ingelheim Investigational Site
    • Manitoba
      • Winnipeg, Manitoba, Canada
        • St. Boniface General Hospital
    • Ontario
      • Courtice, Ontario, Canada
        • Boehringer Ingelheim Investigational Site
      • Hamilton, Ontario, Canada
        • St. Joseph's Hospital Cardiac Research
      • Toronto, Ontario, Canada
        • Toronto General Hospital
      • Toronto, Ontario, Canada
        • Department of Respiratory Medicine
      • Toronto, Ontario, Canada
        • Boehringer Ingelheim Investigational Site
    • Quebec
      • Montreal, Quebec, Canada
        • SMBD--Jewish General Hospital
      • Sherbrooke, Quebec, Canada
        • Centre de Recherche Clinique -CUSE
      • Ste-Foy, Quebec, Canada
        • Hopital Laval
    • Saskatchewan
      • Saskatoon, Saskatchewan, Canada
        • c/o Hemodynamics Offices
  • United States
    • Alabama
      • Birmingham, Alabama, United States
        • Boehringer Ingelheim Investigational Site
    • California
      • Downey, California, United States
        • Boehringer Ingelheim Investigational Site
      • Los Angeles, California, United States
        • University of California - Los Angeles
      • Palo Alto, California, United States
        • Boehringer Ingelheim Investigational Site
    • Colorado
      • Wheat Ridge, Colorado, United States
        • Rocky Mountain Center for Clinical Research
    • Florida
      • Bay Pines, Florida, United States
        • Boehringer Ingelheim Investigational Site
      • Clearwater, Florida, United States
        • Boehringer Ingelheim Investigational Site
      • Pembroke Pines, Florida, United States
        • Boehringer Ingelheim Investigational Site
    • Maryland
      • Wheaton, Maryland, United States
        • Boehringer Ingelheim Investigational Site
    • Missouri
      • St. Louis, Missouri, United States
        • Boehringer Ingelheim Investigational Site
    • New York
      • New Hyde Park, New York, United States
        • Boehringer Ingelheim Investigational Site
    • North Carolina
      • Elizabeth City, North Carolina, United States
        • Boehringer Ingelheim Investigational Site
    • South Carolina
      • Charleston, South Carolina, United States
        • Boehringer Ingelheim Investigational Site
    • Texas
      • Dallas, Texas, United States
        • Boehringer Ingelheim Investigational Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

40 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Outpatients of either sex, aged >/= 40 years with a diagnosis of COPD (FEV1 </= 60% predicted [ECCS criteria] and FEV1/FVC </= 70%)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Time Frame
Trough FEV1 response after 12 weeks of treatment.
Time Frame: after 12 weeks
after 12 weeks

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Time Frame
Trough FEV1 response
Time Frame: after 1, 4 and 8 weeks
after 1, 4 and 8 weeks
Trough FVC response
Time Frame: after 1, 4, 8 and 12 weeks
after 1, 4, 8 and 12 weeks
FEV1 and FVC area under the curve and peak response
Time Frame: after 0, 1, 4, 8 and 12 weeks
after 0, 1, 4, 8 and 12 weeks
Individual FEV1 and FVC measurements at each time point
Time Frame: during study course of 12 weeks
during study course of 12 weeks
Therapeutic response and percentage of responders
Time Frame: after 0 and 12 weeks
after 0 and 12 weeks
Weekly mean pre-dose morning and evening PEFR
Time Frame: during study course of 12 weeks
during study course of 12 weeks
Number of occasions of rescue therapy used per day (PRN salbutamol)
Time Frame: during study course of 12 weeks
during study course of 12 weeks
COPD symptom scores
Time Frame: during 15 weeks
during 15 weeks
Physician's Global Evaluation
Time Frame: during 15 weeks
during 15 weeks
Number of patients with at least one exacerbation of COPD
Time Frame: 15 weeks
15 weeks
time to first exacerbation
Time Frame: 15 weeks
15 weeks
number of exacerbations
Time Frame: 15 weeks
15 weeks
number of exacerbation days
Time Frame: 15 weeks
15 weeks
Patient satisfaction and preference
Time Frame: 12 weeks
12 weeks
All adverse events
Time Frame: during 15 weeks, follow-up period included
during 15 weeks, follow-up period included
Pulse rate and blood pressure for the first three hours following dosing
Time Frame: after 0, 1, 4, 8 and 12 weeks
after 0, 1, 4, 8 and 12 weeks
Routine blood chemistry, haematology and urinalysis
Time Frame: after 12 weeks
after 12 weeks
12-lead ECG
Time Frame: after 12 weeks
after 12 weeks
Physical examination
Time Frame: after 12 weeks
after 12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Boehringer Ingelheim

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
November 1, 2002

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 1, 2003

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
October 14, 2005

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
October 14, 2005

First Posted (Estimate)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
October 18, 2005

Study Record Updates

Last Update Posted (Estimate)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
November 1, 2013

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
October 31, 2013

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
October 1, 2013

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 205.252

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings